A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. We are generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, we are expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, we expect to bring our medicines to patients by leveraging our proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 7.4M | - | 0 | 0 | - | 37M |
| Net Income | -88M | -84M | -81M | -82M | -85M | -27M |
| EPS | $-9.42 | $-9.37 | $-53.08 | $-115.60 | $-120.00 | $-41.00 |
| Free Cash Flow | -70M | -78M | -75M | -58M | -79M | -52M |
| ROIC | -108.1% | -52.1% | -47.8% | -176.1% | -64.3% | -12.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.41 | 0.30 | 0.29 | 0.01 | 0.08 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -94M | -92M | -85M | -83M | -84M | -28M |
| Operating Margin | -1282.0% | - | - | - | - | -74.5% |
| ROE | -54.7% | -43.8% | -47.8% | -64.1% | -64.7% | -13.8% |
| Shares Outstanding | 9M | 9M | 9M | 1M | 1M | 1M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | 29M | 37M | N/A | 0 | 0 | N/A | 7.4M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -19M | -21M | -28M | -84M | -83M | -85M | -92M | -94M |
| Op. Margin | N/A | -71.4% | -74.5% | N/A | N/A | N/A | N/A | -1282.0% |
| Net Income | -19M | -20M | -27M | -85M | -82M | -81M | -84M | -88M |
| Net Margin | N/A | -68.4% | -71.7% | N/A | N/A | N/A | N/A | -1199.5% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -47.0% | -11.8% | -12.8% | -64.3% | -176.1% | -47.8% | -52.1% | -108.1% |
| ROE | -47.4% | -11.8% | -13.8% | -64.7% | -64.1% | -47.8% | -43.8% | -54.7% |
| ROA | -43.0% | -8.9% | -10.0% | -45.7% | -53.2% | -36.6% | -37.3% | -54.7% |
| Cash Flow | ||||||||
| Op. Cash Flow | -17M | 34M | -45M | -76M | -58M | -67M | -60M | -68M |
| Free Cash Flow | -17M | 33M | -52M | -79M | -58M | -75M | -78M | -70M |
| Owner Earnings | -18M | 30M | -56M | -101M | -81M | -73M | -68M | -76M |
| CapEx | 436K | 1.1M | 6.7M | 2.9M | 0 | 7.8M | 18M | 1.9M |
| Maint. CapEx | 654K | 813K | 1.1M | 2.8M | 2.8M | 3.6M | 3.6M | 3.6M |
| Growth CapEx | 0 | 251K | 5.5M | 139K | N/A | 4.2M | 14M | 0 |
| D&A | 654K | 813K | 1.1M | 2.8M | 2.8M | 3.6M | 3.6M | 3.6M |
| CapEx/OCF | N/A | 3.1% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 455K | 3.6M | 10.0M | 22M | 20M | 2.4M | 4.5M | 4.5M |
| Debt Repayment | 0 | 0 | 0 | 0 | 833K | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -42M | -200M | -205M | -78M | -32M | N/A | N/A | -92M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 92M |
| Long-Term Debt | 349K | 180K | 15M | 833K | 10M | N/A | N/A | N/A |
| Debt/Equity | 0.01 | 0.00 | 0.08 | 0.01 | 0.29 | 0.30 | 0.41 | 0.00 |
| Interest Coverage | -70.4 | N/A | N/A | -110.0 | -86.4 | N/A | N/A | N/A |
| Equity | 40M | 167M | 192M | 131M | 69M | 170M | 160M | 162M |
| Total Assets | 45M | 223M | 265M | 185M | 121M | 222M | 226M | 162M |
| Total Liabilities | 4.1M | 56M | 72M | 55M | 52M | 52M | 66M | 63M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -49M | -69M | -95M | -180M | -262M | -183M | -267M | -267M |
| Working Capital | 39M | 169M | 198M | 123M | 66M | 153M | 117M | 117M |
| Current Assets | 43M | 221M | 225M | 135M | 87M | 173M | 132M | 132M |
| Current Liabilities | 3.8M | 53M | 27M | 11M | 21M | 19M | 15M | 15M |
| Per Share Data | ||||||||
| EPS | -626.50 | -114.50 | -41.00 | -120.00 | -115.60 | -53.08 | -9.37 | -9.42 |
| Owner EPS | -29.30 | 43.59 | -87.10 | -142.52 | -114.54 | -7.81 | -7.63 | -8.11 |
| Book Value | 65.32 | 244.83 | 297.69 | 185.37 | 98.05 | 18.10 | 17.98 | 17.15 |
| Cash Flow/Share | -27.51 | 50.06 | -69.88 | -107.77 | -82.52 | -7.17 | -6.73 | -9.01 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.6M | 0.7M | 0.6M | 0.7M | 0.7M | 9.4M | 8.9M | 9.4M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.5 |
| P/FCF | N/A | 18.9 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 3.7 | 5.7 | 1.5 | 1.4 | 2.7 | 2.2 | 0.8 |
| Price/Sales | N/A | 18.3 | 19.0 | N/A | N/A | N/A | N/A | 17.8 |
| FCF Yield | N/A | 5.3% | -4.8% | -41.6% | -60.7% | -16.3% | -21.9% | -53.5% |
| Market Cap | N/A | 627M | 1.1B | 190M | 96M | 462M | 357M | 131M |
| Avg. Price | N/A | 774.20 | 1,084.89 | 791.36 | 117.46 | 49.06 | 50.85 | 13.93 |
| Year-End Price | N/A | 917.00 | 1,686.00 | 269.00 | 136.00 | 49.16 | 40.00 | 13.93 |
Korro Bio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Korro Bio, Inc. (KRRO) has a 5-year average return on invested capital (ROIC) of -70.6%. This is below average and may indicate limited pricing power.
Korro Bio, Inc. (KRRO) has a market capitalization of $131M. It is classified as a small-cap stock.
Korro Bio, Inc. (KRRO) does not currently pay a regular dividend.
Korro Bio, Inc. (KRRO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Korro Bio, Inc. (KRRO) generated $-78 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Korro Bio, Inc. (KRRO) has a debt-to-equity ratio of 0.41. This indicates a conservatively financed balance sheet.
Korro Bio, Inc. (KRRO) reported earnings per share (EPS) of $-9.37 in its most recent fiscal year.
Korro Bio, Inc. (KRRO) has a return on equity (ROE) of -43.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Korro Bio, Inc. (KRRO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Korro Bio, Inc. (KRRO) has a book value per share of $17.98, based on its most recent annual SEC filing.